Literature DB >> 16905683

The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis.

Sonia Abilleira1, Steve Bevan, Hugh S Markus.   

Abstract

Current evidence suggests that matrix metalloproteinases (MMPs) have a role in early atherosclerosis, plaque rupture and myocardial infarction. Polymorphisms in MMP genes have been examined for associations with atherosclerosis, but interpretation is complicated by methodological issues. This article presents a systematic review of these association studies and a meta-analysis of available data for polymorphisms where a sufficient number of studies was available. The 5A allele of the MMP3 5A/6A polymorphism was associated with acute myocardial infarction (odds ratio (OR) 1.26, 95% confidence interval (CI) 1.1 to 1.4, p<0.001), suggesting its role in plaque rupture. There was no association with the functional MMP9 -1562C/T polymorphism (OR 1.11, 95% CI 1.0 to 1.3, p = 0.18). Current data provide evidence for the role of MMP3 polymorphism in plaque destabilisation, but elucidation of the role of other MMP gene variants in atherosclerosis will depend on better study design, including a larger sample size, extensive screening of individual genes with haplotype analysis and replication of studies to avoid publication bias.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16905683      PMCID: PMC2563195          DOI: 10.1136/jmg.2006.040808

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  70 in total

1.  Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes.

Authors:  H Kai; H Ikeda; H Yasukawa; M Kai; Y Seki; F Kuwahara; T Ueno; K Sugi; T Imaizumi
Journal:  J Am Coll Cardiol       Date:  1998-08       Impact factor: 24.094

2.  Gelatinase B C(-1562)T polymorphism in relation to ischaemic heart disease.

Authors:  W Haberbosch; A Gardemann
Journal:  Scand J Clin Lab Invest       Date:  2005       Impact factor: 1.713

3.  Matrix metalloproteinase3 and 9 gene promoter polymorphisms: joint action of two loci as a risk factor for coronary artery complicated plaques.

Authors:  Perttu J Pöllänen; Terho Lehtimäki; Jussi Mikkelsson; Erkki Ilveskoski; Tarja Kunnas; Markus Perola; Antti Penttilä; Kari M Mattila; Seppo T Nikkari; Kirsi Syrjäkoski; Pekka J Karhunen
Journal:  Atherosclerosis       Date:  2004-12-18       Impact factor: 5.162

4.  Variation in the matrix metalloproteinase-1 gene and risk of coronary heart disease.

Authors:  Shu Ye; Catharine R Gale; Christopher N Martyn
Journal:  Eur Heart J       Date:  2003-09       Impact factor: 29.983

5.  Genetic variations of matrix metalloproteinase-1 and -3 promoter regions and their associations with susceptibility to myocardial infarction in Japanese.

Authors:  Takefumi Nojiri; Hiroyuki Morita; Yasushi Imai; Koji Maemura; Minoru Ohno; Ken Ogasawara; Tadanori Aizawa; Akira Saito; Doubun Hayashi; Yasunobu Hirata; Takao Sugiyama; Tsutomu Yamazaki; Ryozo Nagai
Journal:  Int J Cardiol       Date:  2003-12       Impact factor: 4.164

6.  Association of gene polymorphisms with coronary artery disease in low- or high-risk subjects defined by conventional risk factors.

Authors:  Akihiro Hirashiki; Yoshiji Yamada; Yosuke Murase; Yoriyasu Suzuki; Hiroki Kataoka; Yasutsugu Morimoto; Toru Tajika; Toyoaki Murohara; Mitsuhiro Yokota
Journal:  J Am Coll Cardiol       Date:  2003-10-15       Impact factor: 24.094

7.  Premature coronary artery disease shows no evidence of linkage to loci encoding for tissue inhibitors of matrix metalloproteinases.

Authors:  Micha F Dorsch; Jenny A Barrett; Richard A Lawrance; Azhar Maqbool; Nigel P Durham; Stacey Ellis; Nilesh J Samani; Tim Bishop; Stephen G Ball; Anthony J Balmforth; Alistair S Hall
Journal:  J Hum Genet       Date:  2003-09-19       Impact factor: 3.172

8.  Synergistic effect of stromelysin-1 (matrix metallo-proteinase-3) promoter 5A/6A polymorphism with smoking on the onset of young acute myocardial infarction.

Authors:  Ping-Yen Liu; Jyh-Hong Chen; Yi-Heng Li; Hua-Lin Wu; Guey-Yueh Shi
Journal:  Thromb Haemost       Date:  2003-07       Impact factor: 5.249

9.  The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lopid Coronary Angiography Trial.

Authors:  S E Humphries; L A Luong; P J Talmud; M H Frick; Y A Kesäniemi; A Pasternack; M R Taskinen; M Syvänne
Journal:  Atherosclerosis       Date:  1998-07       Impact factor: 5.162

10.  The 5A/6A polymorphism of the stromelysin-1 gene and restenosis after percutaneous coronary interventions.

Authors:  Petra Hoppmann; Werner Koch; Albert Schömig; Adnan Kastrati
Journal:  Eur Heart J       Date:  2004-02       Impact factor: 29.983

View more
  39 in total

1.  Effect of Qingre Quyu Granule (清热祛瘀颗粒) on stabilizing plaques in the brachiocephalic artery of apolipoprotein E deficient mice.

Authors:  Yong Wang; Wen-li Cheng; Yuan-nan Ke; Zhe Cai; Li Chen; Yuan Xi; Pu Wang; Jian Guo; Hong Li; Cong-xin Huang
Journal:  Chin J Integr Med       Date:  2010-09-25       Impact factor: 1.978

Review 2.  Progress in matrix metalloproteinase research.

Authors:  Gillian Murphy; Hideaki Nagase
Journal:  Mol Aspects Med       Date:  2008-05-24

3.  Association of matrix metalloproteinase-2 gene promoter polymorphism with myocardial infarction susceptibility in a Mexican population.

Authors:  Ivan Delgado-Enciso; Nelida A Gonzalez-Hernandez; Luz M Baltazar-Rodriguez; Rebeca O Millan-Guerrero; Oscar Newton-Sanchez; Alfonso Bayardo-Noriega; Alfonso Aleman-Mireles; Irma G Enriquez-Maldonado; Ma J Anaya-Carrillo; Augusto Rojas-Martinez; Rocio Ortiz-Lopez
Journal:  J Genet       Date:  2009-08       Impact factor: 1.166

Review 4.  Genetics of cardiovascular disease: Importance of sex and ethnicity.

Authors:  Stacey J Winham; Mariza de Andrade; Virginia M Miller
Journal:  Atherosclerosis       Date:  2015-03-16       Impact factor: 5.162

5.  Circulating matrix metalloproteinases in adolescents with hypertrophic cardiomyopathy and ventricular arrhythmia.

Authors:  Justin P Zachariah; Steven D Colan; Peter Lang; John K Triedman; Mark E Alexander; Edward P Walsh; Charles I Berul; Frank Cecchin
Journal:  Circ Heart Fail       Date:  2012-05-24       Impact factor: 8.790

6.  A novel matrix metalloproteinase 2 (MMP2) terminal hemopexin domain mutation in a family with multicentric osteolysis with nodulosis and arthritis with cardiac defects.

Authors:  Beyhan Tuysuz; Rebecca Mosig; Gürkan Altun; Selim Sancak; Marc J Glucksman; John A Martignetti
Journal:  Eur J Hum Genet       Date:  2008-11-05       Impact factor: 4.246

7.  Allele-specific regulation of matrix metalloproteinase-3 gene by transcription factor NFkappaB.

Authors:  Veronika Souslova; Paul A Townsend; Jelena Mann; Chris M van der Loos; Anna Motterle; Fulvio D'Acquisto; Derek A Mann; Shu Ye
Journal:  PLoS One       Date:  2010-03-25       Impact factor: 3.240

8.  Functional polymorphisms of matrix metallopeptidase-9 and risk of coronary artery disease in a Chinese population.

Authors:  Hong Zhi; Hua Wang; Liqun Ren; Zhiyang Shi; Haiyan Peng; Lunbiao Cui; Genshan Ma; Xingzhou Ye; Yi Feng; Chengxing Shen; Xiangjun Zhai; Chenyu Zhang; Ke Zen; Naifeng Liu
Journal:  Mol Biol Rep       Date:  2009-03-13       Impact factor: 2.316

9.  NF-kappaB and ZBP-89 regulate MMP-3 expression via a polymorphic site in the promoter.

Authors:  Ruth C Borghaei; Grzegorz Gorski; Masoud Javadi
Journal:  Biochem Biophys Res Commun       Date:  2009-03-09       Impact factor: 3.575

10.  Accumulation of gene polymorphisms related to plaque disruption and thrombosis is associated with cerebral infarction in subjects with type 2 diabetes.

Authors:  Naoto Katakami; Mitsuyoshi Takahara; Hideaki Kaneto; Ikki Shimizu; Keizo Ohno; Fukashi Ishibashi; Takeshi Osonoi; Atsunori Kashiwagi; Ryuzo Kawamori; Iichiro Shimomura; Munehide Matsuhisa; Yoshimitsu Yamasaki
Journal:  Diabetes Care       Date:  2009-11-23       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.